Medical and hoarse bottles are seen with the Novo Nordisk logo on a background screen.
Norfuto Norfuto Gety pictures
Danish pharmaceutical giant Novo Nordsk On Wednesday, I reported a net profit for better than expected in the fourth quarter, amid the high demand for obesity drugs in Wegovy.
The net profit for the fourth quarter reached 28.23 billion Danish krons (3.98 billion dollars), compared to 26.09 billion kronor.
The net profit of the entire year was 100.99 billion Danish Kroner, and also won 99.14 billion Danish Krones for 2024.
Drug maker post 107% Annual on the basis of Wegovy sales to 19.87 billion Danish Crohn ($ 2.76 billion) in the three months until the end of December, a 20.02 billion Danish Crohn’s expectations were lost by analysts in the FactSet survey late Tuesday.
Novo Nordsek escaped a wave of global demand for the GLP-1 obesity treatments. GLP-1S, which forms the Wegovy basis from Novo and competition Eli Lily‘
Investors are now monitoring updates on other obese drug candidates, including the expected experimental CAGRISEMA Treatment. The results of the Cagrisema experience in the late stage led to the disappointment of markets in December after showing the average weight reduction by 22.7 %, less than 25 % of Novo had previously expected.
The results of the experiment treated the expectations that CAGRISEMA will appear as a obesity medicine from the next generation in Novo, combining the active ingredient-ingredient in Wegovy-with analog attachments, a form of weight loss treatment.
However, the positive results in the early stage of the aycretin weekend, which similarly employ the hormone of the pancreas, led the stocks to the top of last month.
This is an urgent news story and will be updated soon.
